Skip to main content

Table 2 Antimicrobial consumption in DOT/1000 PD during the study

From: The effect of a rapid molecular blood test on the use of antibiotics for nosocomial sepsis: a randomized clinical trial

Antimicrobial consumption: All patients Positive test
Intervention group Control group P value Intervention group Control group P value
DOT/1000 PD, median, (IQR) (n = 100) (n = 100) (n = 19) (n = 25)
- All antimicrobial 1621 (1196–2388) 2000 (1440–2433) 0.067* 1429 (1071–2000) 1889 (1357–2563) 0.017*
- Antimicrobial for Gram-negative bacteria coveragea 1000 (768–1466) 1071 (786–1665) 0.248* 1071 (786–1429) 1286 (536–1857) 0.427*
- Antimicrobial for Gram-positive coverageb 786 (554–1000) 866 (641–1000) 0.259* 71 (71–1000) 786 (354–1000) 0.013*
  1. *Mann–Whitney test
  2. IQR interquartile range
  3. aPiperacillin-tazobactam, fluoroquinolones, cephalosporins, aminoglycosides, tigecycline, trimethoprim-sulfamethoxazole, meropenem, polymyxin B/E
  4. bGlycopeptides, linezolid, daptomycin, andoxacillin